label
int64
1
1
id
stringlengths
10
12
original_id
stringlengths
8
9
text
stringlengths
347
29.5k
1
172539239_0
172539239
CORPORACION AMERICA AIRPORTS S.A. Form 20-F Filed on 27-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001144204-18-023178 Included Items 1. 20-F: FORM 20-F 2. EX-1.1: EXHIBIT 1.1 3. EX-8.1: EXHIBIT 8.1 4. EX-12.1: EXHIBIT 12.1 5. EX-12.2: EXHIBIT 12.2 6. EX-13.1: EXHIBIT 13.1 7. EX-13.2: EXHIBIT 13.2 UNITED STATES...
1
172539239_1
172539239
, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 For the transition period from __________ to ___________ OR ¨ SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 Date of event requiring this shell company report ______________ C...
1
172539239_2
172539239
exchange in which registered New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as...
1
172539239_3
172539239
) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ¨ Yes x No Indicate by check mark whether the registrant has submitted electronically ...
1
172539239_b0
172539239
ES-OXLEYACT OF 2002 In connection with the Annual Report of Corporación América Airports S.A. (the "Company") on Form 20-F for the fiscal year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report"), I, Martín Francisco Antranik Eurnekian, Chief Executive Off...
1
172539239_b1
172539239
has materially affected, or is reasonably likely to materially affect the company's internal control over financial reporting. 5. The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit c...
1
172540039_0
172540039
Adecoagro S.A. Form 20-F Filed on 27-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001628280-18-005268 Included Items 1. 20-F 2. EX-1.1: EXHIBIT 1.1 3. EX-4.43: EXHIBIT 4.43 4. EX-8.1: EXHIBIT 8.1 5. EX-12.1: EXHIBIT 12.1 6. EX-12.2: EXHIBIT 12.2 7. EX-13.1: EXHIBIT 13.1 8. EX-13.2: EXHIBIT 13.2 9. EX-15.1: EXHIBIT ...
1
172540039_1
172540039
OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 FOR THEFISCAL YEAR ENDED ON DECEMBER 31, þ 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 FOR THETRANSITION PERIOD FROM TO ________________ OR ¨ SHELL COMPANYREPORT PU...
1
172540039_2
172540039
Naos Building, 6, Rue Eugène Ruppert, L - 2453 Luxembourg Email: catherine.Drissens@intertrustgroup.com Tel: +352.26449.167 (Name, Telephone, E-Mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Name ...
1
172540039_3
172540039
of the Securities Exchange Act of 1934. Yes ¨ No þ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports)...
1
172540039_b0
172540039
.50% Perpetuity growth rate 2.00% 2.00% UMA Disclosure of information for cash-generating units [line items] Financial projections (in years) 4 years 4 years AVI Disclosure of information for cash-generating units [line items] Financial projections (in years) 7 years 7 years Bottom of range Disclosure of i...
1
172540039_b1
172540039
-generating units [line items] Goodwill 2,622 2,564 Brazil Disclosure of information for cash-generating units [line items] Goodwill $ 7,317 $ 7,425 Brazil | Cash-generating units Disclosure of information for cash-generating units [line items] Goodwill 7,634 7,456 Closing net book value of PPE items and ...
1
172543714_0
172543714
MATERIALISE NV Form 20-F Filed on 30-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001193125-18-143179 Included Items 1. 20-F 2. EX-1.1 3. EX-4.9 4. EX-8.1 5. EX-12.1 6. EX-12.2 7. EX-13.1 8. EX-13.2 9. EX-23.1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F R...
1
172543714_1
172543714
THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36515 MATERIALISE NV (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) Kingdom of Belgium (Jurisdiction of incorporation or organization) Technologielaan 15, 3001 Leuven, Belgium (Addres...
1
172543714_2
172543714
to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None. Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None. The number of outstanding shares of each of the issuer's classes of capi...
1
172543714_3
172543714
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be...
1
172543714_b0
172543714
my knowledge: (i) the Report fully complies with the requirements of section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: April ...
1
172543714_b1
172543714
over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over finan...
1
172543848_0
172543848
Forward Pharma A/S Form 20-F Filed on 30-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001047469-18-003354 Included Items 1. 20-F 2. EX-8.1 3. EX-12.1 4. EX-12.2 5. EX-13.1 6. EX-15.1 7. XBRL (render) Use these links to rapidly review the document TABLE OF CONTENTS Forward Pharma A/S Table of Contents UNITED STATE...
1
172543848_1
172543848
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report............... Commission file number 001-36686 Forward Pharma A/S (Exact name of Registrant as specified in its charter) Forward Pharma A/S (Translation of Registrant's name into E...
1
172543848_2
172543848
represents two ordinary shares Each ADS represents two ordinary shares Securities registered or to be registered pursuant to Section 12(g) of the Act. Not Applicable (Title of Class) Table of Contents Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. Not Applicable (Titl...
1
172543848_3
172543848
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 day...
1
172543848_b0
172543848
000 Consultant two | Deferred shares Disclosure of transactions between related parties [line items] Shares outstanding | EquityInstruments 194,000 Board of Directors Disclosure of transactions between related parties [line items] Compensation $ 373,000 $ 87,000 $ 35,000 Share - based compensation 1,300...
1
172543848_b1
172543848
parties 0 Share - based compensation paid $ 223,000 $ 3,290,000 $ 5,500,000 Deferred shares Disclosure of transactions between related parties [line items] Granted | EquityInstruments 55,000 Shares outstanding | EquityInstruments 700,000 3,517,000 4,814,000 5,686,000 Granted (after Share Split) | Equi...
1
172544002_0
172544002
NATUZZI S P A Form 20-F Filed on 30-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001193125-18-143394 Included Items 1. 20-F: FORM 20-F 2. EX-4.8 3. EX-4.9 4. EX-8.1 5. EX-12.1 6. EX-12.2 7. EX-13.1 Table of Contents Natuzzi S.p.A Annual Report on Form 20-F 2017 Table of Contents UNITED STATES SECURITIES AND E...
1
172544002_1
172544002
70029, Santeramo in Colle, Bari, Italy (Address of principal executive offices) Mr. Pietro Direnzo Tel.: +39 080 8820 812; pdirenzo@natuzzi.com; Via Iazzitiello 47, 70029 Santeramo in Colle, Bari, Italy (Name, telephone, e-mail and/or facsimile number and address of company contact person) Securities registered or to ...
1
172544002_2
172544002
, 2017 54,853,045 Ordinary Shares Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) ...
1
172544002_3
172544002
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-a...
1
172544002_b0
172544002
or is reasonably likely to materially affect, the company's internal control over financial reporting; and 5. The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the compan...
1
172544002_b1
172544002
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our ...
1
172544082_0
172544082
EDAP TMS SA Form 20-F Filed on 30-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001171843-18-003197 Included Items 1. 20-F: FORM 20-F 2. EX-1.1: EXHIBIT 1.1 3. EX-8.1: EXHIBIT 8.1 4. EX-12.1: EXHIBIT 12.1 5. EX-12.2: EXHIBIT 12.2 6. EX-13.1: EXHIBIT 13.1 7. EX-15.1: EXHIBIT 15.1 8. XBRL (render) As filed with the ...
1
172544082_1
172544082
the Fiscal Year Ended December 31, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from ________ to _________ OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 Date of the event requiring this shel...
1
172544082_2
172544082
69120 Vaulx-en-Velin, France (Name, Telephone, E-mail and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered American Depositary Shares, each representing One Ordinary Share Ordinary Share...
1
172544082_3
172544082
Yes _______ No ___X___ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subje...
1
172544082_b0
172544082
(4,131) Balance 14,266 19,450 19,212 SEC Schedule, 12-09, Allowance, Credit Loss [Member] Balance 960 1,091 1,274 Charges to costs and expenses 69 103 124 Deductions: write-off and others (233) (307) Balance 1,029 960 1,091 SEC Schedule, 12-09, Reserve, Inventory [Member] Balance 803 728 741 C...
1
172544082_b1
172544082
Segment operating income (loss) (311) Total Assets Capital expenditures Long-lived assets Goodwill FDA [Member] | Product [Member] Revenues FDA [Member] | HIFU Treatments and Devices Leased [Member] Revenues FDA [Member] | Parts and Services [Member] Revenues FDA [Member] | Product and Services, Excluding ...
1
172544372_0
172544372
Nexa Resources S.A. Form 20-F Filed on 30-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001104659-18-028667 Included Items 1. 20-F 2. EX-8 3. EX-12.1 4. EX-12.2 5. EX-13.1 Table of Contents As filed with the Securities and Exchange Commission on April 30, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was...
1
172544372_1
172544372
L-2540, Luxembourg Grand Duchy of Luxembourg (Address of principal executive offices) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Common shares, each with par value of US$1.00 Name of Each Exchange on Which Registered New York Stock Exchange Securities registe...
1
172544372_2
172544372
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registra...
1
172544372_3
172544372
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ...
1
172544372_b0
172544372
the period covered by this report based on such evaluation; and (c) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's inter...
1
172544372_b1
172544372
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statemen...
1
172544577_0
172544577
Merus N.V. Form 20-F Filed on 30-Apr-2018 Period ­ 31-Dec-2017 Accession number: 0001193125-18-143856 Included Items 1. 20-F: FORM 20-F 2. EX-1.1 3. EX-4.1 4. EX-4.2 5. EX-4.3 6. EX-4.7 7. EX-4.8 8. EX-4.9 9. EX-4.10 10. EX-4.11 11. EX-4.12 12. EX-4.15.1 13. EX-4.19 14. EX-12.1 15. EX-12.2 16. EX-13.1 17. EX-13.2 18. E...
1
172544577_1
172544577
OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 For the fiscal year ended December 31, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 For the transition period from to OR SHELL COMPANYREPORT PURSUANT TO SECTION 13...
1
172544577_2
172544577
800 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Common shares, nominal value 0.09 per share Name of each exchange on which registered The Nasdaq Stock Market LLC Securities ...
1
172544577_3
172544577
No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requ...
1
172544577_b0
172544577
closure of finance lease and operating lease by lessee [line items] Minimumlease payments payable under non cancellable operating lease 2,499 Less than one year [member] Disclosure of finance lease and operating lease by lessee [line items] Minimumlease payments payable under non cancellable operating lease 602 B...
1
172544577_b1
172544577
between related parties [line items] Ownership interest held by shareholders 5.00% Bottom of range [member] | Sofinnova Venture Partners Nine Limited Partnership [member] Disclosure of transactions between related parties [line items] Ownership interest held by shareholders 5.00% Top of range [member] | Biophra...
1
172602064_0
172602064
BT GROUP PLC Form 20-F Filed on 24-May-2018 Period ­ 31-Mar-2018 Accession number: 0001193125-18-172711 Included Items 1. 20-F 2. EX-7.1 3. EX-12.1 4. EX-12.2 5. EX-13.1 6. EX-15.1 7. EX-15.2 8. EX-15.3 9. EX-15.4 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (...
1
172602064_1
172602064
SUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 1-08819 BT Group plc (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English)...
1
172602064_2
172602064
NewYork Stock Exchange* * Not for trading, but only in connection with the registration of American Depositary Shares representing these shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for wh...
1
172602064_3
172602064
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requireme...
1
172602064_b0
172602064
None of the reports of PwC on those financial statements contained an adverse opinion or disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles. During those fiscal years there were no disagreements with PwC, whether or not resolved, on any matter of accounting prin...
1
172602064_b1
172602064
London Stock Exchange in 1984 and PwC's reappointment had not been subject to a tender until 2017 when the Audit & Risk Committee recommended to the Board that an audit tender process be undertaken with a view to appointing a new auditor for the financial year 2018/19. PwC advised the Audit & Risk Committee on 11 Apri...
1
172639425_0
172639425
Castle Brands Inc Form 10-K Filed on 14-Jun-2018 Period ­ 31-Mar-2018 Accession number: 0001493152-18-008701 Included Items 1. 10-K 2. EX-21.1 3. EX-23.1 4. EX-31.1 5. EX-31.2 6. EX-32.1 7. XBRL (render) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO ...
1
172639425_1
172639425
S. Employer Identification No.) 122 East 42nd Street, Suite 5000 NewYork, NewYork (Address of principal executive offices) 10168 (Zip Code) Registrant's telephone number, including area code (646) 356-0200 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Common stock, $0.01 par value...
1
172639425_2
172639425
been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of thi...
1
172639425_3
172639425
. [ ] Large accelerated filer [ ] Non-accelerated filer [ ] Emerging growth company [X] Accelerated filer [ ] Smaller reporting company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account...
1
172639425_b0
172639425
,375) (469,798) (210,856) (170,116) 1,089,124 1,359,145 809,662 Net (loss) income attributable to common Stockholders $ (336,434) $ 465,580 $ (1,682) $ (946,396) $ 191,350 $ 422,566 $ (700,710) $ (765,819) $ (818,932) $ (852,613) $ (2,516,368) Net (loss) income per common share, basic, attributable to $ (0....
1
172639425_b1
172639425
$ $ $ [1] $ [1] $ [1] 24,071,457 24,079,623 20,894,150 20,852,287 22,580,876 18,309,539 19,627,791 16,750,925 89,897,517 77,269,131 72,220,368 Gross profit 9,407,147 9,677,937 8,534,249 8,578,619 9,586,742 7,670,240 7,727,260 6,716,115 36,206,952 31,700,357 28,553,570 Net (loss) income 190,185 664,603 280,6...
1
172650461_0
172650461
Medtronic Plc Form 10-K Filed on 22-Jun-2018 Period ­ 27-Apr-2018 Accession number: 0001613103-18-000024 Included Items 1. 10-K 2. EX-10.50: EXHIBIT 10.50 3. EX-10.51: EXHIBIT 10.51 4. EX-10.52: EXHIBIT 10.52 5. EX-10.53: EXHIBIT 10.53 6. EX-12.1: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES 7. EX-21: LIST OF SUBS...
1
172650461_1
172650461
.2: CERTIFICATION OF CFO PURSUANT TO SECTION 906 14. XBRL (render) Table of Contents UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 10-K x Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 27, 2018. o Transition rep...
1
172650461_2
172650461
Title of each class Ordinary shares, par value $0.0001 per share Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o Name of each exchange on which registered NewYork Sto...
1
172650461_3
172650461
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in...
1
172650461_b0
172650461
2,668 $ 4,929 (3,471) 113 (518) 3,339 2,821 4,114 (1,266) (1,046) (5,406) 9,924 0 0 (14) 2,192 (22) 7 0 0 (3,011) 0 0 0 (6,163) (4,005) 5,679 82 (7,433) 113 (1,014) 3,682 $ 2,668 Schedule II (Details) - USD ($) $ in Millions 12 Months Ended Apr. 27, 2018 Apr. 28, 2017 Apr. 29, 2016 Allowance for Doubtful Accounts...
1
172650461_b1
172650461
) Dividends to shareholders 0 Issuance of ordinary shares 0 Repurchase of ordinary shares 0 Net intercompany loan borrowings (repayments) (9,969) Intercompany dividend paid (1,048) Capital contributions received 5,757 Other financing activities (2) Net cash used in financing activities (11,597) Effect ...
1
172658669_0
172658669
Modern Media Acquisition Corp. Form 10-K Filed on 28-Jun-2018 Period ­ 31-Mar-2018 Accession number: 0001193125-18-206296 Included Items 1. 10-K: FORM 10-K 2. EX-31.1: EXHIBIT 31.1 3. EX-31.2: EXHIBIT 31.2 4. EX-32.1: EXHIBIT 32.1 5. EX-32.2: EXHIBIT 32.2 6. XBRL (render) Table of Contents UNITED STATES SECURITIES A...
1
172658669_1
172658669
MODERN MEDIA ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 47-1277598 (IRS Employer Identification No.) 1180 Peachtree Street, N.E. Suite 2400 Atlanta, GA (Address of principal executive offices) 30309 (Zip Code) Registrant's tele...
1
172658669_2
172658669
daq Capital Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d)...
1
172658669_3
172658669
check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form ...
1
172658669_b0
172658669
,653 $ 158,106 $ (615) $ 340 $ 302 $ 297 $ 670,812 $ 324 $ 1,187 Loss (income) fromoperations (144,061) (194,992) (173,653) (158,106) 615 (340) (302) (297) (670,812) (324) (1,187) Interest income 604,453 474,396 429,200 50,860 1,558,909 Net income (loss) $ 306,569 $ 126,944 $ 126,327 $ (107,246) $ 615 $ (3...
1
172658669_b1
172658669
net of federal tax benefit 0.00% Change in valuation allowance 17.50% Income tax provision 49.00% Fair Value Measurements Summary of Assets Measured at Fair Value on Recurring Basis (Detail) Mar. 31, 2018 USD ($) Assets: Cash and marketable securities held in Trust Account $ 210,502,923 Fair Value, Inputs, ...
1
172687161_0
172687161
Akari Therapeutics Plc Form 20-F Filed on 18-Jul-2018 Period ­ 31-Dec-2017 Accession number: 0001144204-18-038891 Included Items 1. 20-F: FORM 20-F 2. EX-10.19: EXHIBIT 10.19 3. EX-10.20: EXHIBIT 10.20 4. EX-21.1: EXHIBIT 21.1 5. EX-23.1: EXHIBIT 23.1 6. EX-23.2: EXHIBIT 23.2 7. EX-31.1: EXHIBIT 31.1 8. EX-31.2: EXHIBI...
1
172687161_1
172687161
) OR (g) OF THESECURITIES EXCHANGEACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 For the fiscal year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934 OR ¨ SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR...
1
172687161_2
172687161
, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class American Depositary Shares, each representing 100 Ordinary Shares, par value £0.01 per share Ordinary Shares, £0.01 par value per share* Name of e...
1
172687161_3
172687161
Yes x No If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. ¨ Yes x No Note ­ Checking the box above will not relieve any registrant required to file reports pursuant to Sec...
1
172687161_b0
172687161
Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 19.25% 20.00% 20.25% Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total $ 3,800,000 Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total 14.50% Foreign Tax Authority [Member] Operating Loss Carryforwards [Line...
1
172687161_b1
172687161
596 Change of tax rate due to U.S. tax reform 2,506,519 0 0 Tax rate difference in foreign jurisdictions (697,127) 2,341,113 (1,964,914) Income tax expense $ 0 $ 0 $ 0 Taxes (Details 3) - USD ($) Dec. 31, 2017 Dec. 31, 2016 Deferred tax assets Stock-based compensation $ 1,464,527 $ 994,618 Litigation set...
1
172715168_0
172715168
Seagate Technology Plc Form 10-K Filed on 03-Aug-2018 Period ­ 29-Jun-2018 Accession number: 0001193125-18-238271 Included Items 1. 10-K 2. EX-10.52 3. EX-21.1 4. EX-23.1 5. EX-31.1 6. EX-31.2 7. EX-32.1 8. XBRL (render) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1...
1
172715168_1
172715168
(State or other jurisdiction of incorporation or organization) 98-0648577 (I.R.S. Employer Identification Number) 38/39 Fitzwilliam Square Dublin 2, Ireland (Address of principal executive offices) Registrant's telephone number, including area code: (353) (1) 234-3136 Securities registered pursuant to Section 12 (...
1
172715168_2
172715168
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File r...
1
172715168_3
172715168
" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer Non-accelerated filer Emerging growth company (Do not check if a smaller reporting company) Accelerated filer Smaller reporting company If an emerging growth company, indicate by check mark if the regist...
1
172715168_b0
172715168
minimumlease payments for operating leases $ 109 Guarantees (Narrative) (Details) 12 Months Ended Jun. 29, 2018 USD ($) Schedule of Fiscal Years [Line Items] intellectual property indemnification obligations $ 0 intellectual property indemnification obligations $ 0 Minimum [Member] Schedule of Fiscal Years [Li...
1
172715168_b1
172715168
($) $ in Millions 12 Months Ended Jun. 29, 2018 Jun. 30, 2017 Jul. 01, 2016 Leases [Abstract] Total rent expense for all land, facility and equipment operating leases, net of sublease income $ 22 $ 29 $ 43 Total sublease rental income 3 $ 2 $ 3 Total future lease income to be recognized for existing sublease...
1
172728956_0
172728956
CIMPRESS N.V. Form 10-K Filed on 10-Aug-2018 Period ­ 30-Jun-2018 Accession number: 0001262976-18-000052 Included Items 1. 10-K 2. EX-3.1: EXHIBIT 3.1 ARTICLES OF ASSOCIATION 3. EX-10.28: EXHIBIT 10.28 AMENDMENT NO.9 TO EMPLOYMENT AGREEMENT WITH ROBERT S. KEANE 4. EX-21.1: EXHIBIT 21.1 SUBSIDIARIES OF CIMPRESS N.V. 5. ...
1
172728956_1
172728956
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TOSECTION13 OR15(d) OFTHESECURITIES EXCHANGEACT OF1934 For the fiscal year ended June 30, 2018 or o TRANSITIONREPORT PURSUANT TOSECTION13 OR15(d) OFTHESECURIT...
1
172728956_2
172728956
Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Name of Exchange on Which Registered OrdinaryShares, 0.01 par value NASDAQ Global Select Market Securities registered pursuant to Section 12(g) of the Act: None _________________________________ Indicate by check mark if the registr...
1
172728956_3
172728956
pursuant to Rule 405 of Regulation S-T(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o Indicate by check mark if disclosure of delinquent filers pursuant to Item405 of Regulation S-K is not contained here...
1
172728956_b0
172728956
585 576,851 443,713 2,613,545 2,141,095 1,788,044 Revenue 2,592,541 2,135,405 1,788,044 Cost of revenue 316,550 319,209 360,285 283,755 279,077 268,482 276,366 213,050 1,279,799 [1] 1,036,975 [1] 773,640 [1] Net income (loss) (5,639) (1,602) 30,623 23,406 (34,513) (42,678) 35,022 (30,030) 46,788 (72,199) 50,411 ...
1
172728956_b1
172728956
Restructuring Cost and Reserve [Line Items] Restructuring Charges $ 1,116 Other Restructuring [Member] | Central and corporate costs Restructuring Cost and Reserve [Line Items] Restructuring Charges $ 56 [1] Share-based compensation is allocated as follows: Quarterly Financial Data (unaudited) (Details) - USD...
1
172762682_0
172762682
Atlassian Corp Plc Form 20-F Filed on 30-Aug-2018 Period ­ 30-Jun-2018 Accession number: 0001650372-18-000038 Included Items 1. 20-F 2. EX-12.1: EXHIBIT 12.1 3. EX-12.2: EXHIBIT 12.2 4. EX-12.3: EXHIBIT 12.3 5. EX-13.1: EXHIBIT 13.1 6. EX-13.2: EXHIBIT 13.2 7. EX-13.3: EXHIBIT 13.3 8. EX-21.1: EXHIBIT 21.1 9. EX-23.1: ...
1
172762682_1
172762682
SUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934 For the fiscal year ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934 OR ¨ SHELLCOMPANYREPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934 Commission File Number 001-37651...
1
172762682_2
172762682
Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Class A Ordinary Shares NASDAQ Global Select Market Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for whichthere is a repor...
1
172762682_3
172762682
reports pursuant to Section 13 or 15(d) ofthe Securities Exchange Act of1934 fromtheir obligations under those Sections. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ofthe Securities Exchange Act of1934 during the preceding 12 months (or for such s...
1
172762682_b0
172762682
2.04 Weighted Average Exercise Price, exercised (USD per share) | $ 1.93 1.64 Weighted Average Exercise Price, ending balance (USD per share) | $ $ 2.41 $ 2.21 Class B ordinary shares Disclosure of terms and conditions of share-based payment arrangement [line items] Shares Available for Grant, beginning balan...
1
172762682_b1
172762682
61 354,112 $ 0.60 3.07 $ 0.42 0.66 $ 0.63 520,271 $ 0.63 520,271 $ 0.63 0.92 12 Months Ended Share-based Payments Class B activity (Details) Jun. 30, 2018 Jun. 30, 2017 USD ($) USD ($) shares shares Disclosure of terms and conditions of share-based payment arrangement [line items] Shares Available for Grant, be...
1
172889321_0
172889321
Autolus Therapeutics Plc Form 20-F Filed on 23-Nov-2018 Period ­ 30-Sep-2018 Accession number: 0001730463-18-000005 Included Items 1. 20-F 2. EX-2.3: EXHIBIT 2.3 3. EX-12.1: EXHIBIT 12.1 4. EX-12.2: EXHIBIT 12.2 5. EX-13.1: EXHIBIT 13.1 6. EX-15.1: EXHIBIT 15.1 7. XBRL (render) UNITED STATES SECURITIES AND EXCHANGE C...
1
172889321_1
172889321
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to OR o SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number: 001-38547 Autolus Therapeutics plc (Exact name ...
1
172889321_2
172889321
one ordinary share, nominal value $0.000042 per share Ordinary shares, nominal value $0.000042 per share* Name of each exchange on which registered The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC* * Not for trading, but only in connection with the registration of the American Depositary Shares* Securities re...
1
172889321_3
172889321
) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was requi...